EU/3/13/1217: Orphan designation for the treatment of primary sclerosing cholangitis

(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)

Overview

On 16 January 2014, orphan designation (EU/3/13/1217) was granted by the European Commission to Lumena Pharma UK Limited, United Kingdom, for (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride for the treatment of primary sclerosing cholangitis.

The sponsorship was transferred to Shire Pharmaceuticals Ireland Limited, Ireland, in September 2016 and subsequently to SFL Regulatory Services GmbH, Austria, in March 2019.

The sponsorship was transferred to Granzer Regulatory Consulting & Services, Germany in December 2019.

The sponsorship was transferred to Mirum Pharmaceuticals International B.V., Netherlands, in September 2021.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in June 2022 on request of the Sponsor.

Key facts

Active substance
(4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride (maralixibat chloride)
Intended use
Treatment of primary sclerosing cholangitis
Orphan designation status
Withdrawn
EU designation number
EU/3/13/1217
Date of designation
16/01/2014
Sponsor

Mirum Pharmaceuticals International B.V.
Kingsfordweg 151
1043 GR Amsterdam
Noord-Holland
Netherlands
Tel: +31 204919191
E-mail: badr.fathi@mirumpharma.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

This medicine is now known as maralixibat chloride.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating